

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-20. (cancelled)

21. (currently amended) A method of treating a patient suffering from thrombotic thrombocytopenic purpura (TTP) which comprises, administering to said patient a dosage of about 1 $\mu\text{g/kg/hr}$ to about 50 $\mu\text{g/kg/hr}$ of recombinant human activated protein C.

22. (currently amended) The method of Claim 21 wherein the dosage is about ~~[[6]]~~ 5 $\mu\text{g/kg/hr}$ to about ~~[[36]]~~ 30 $\mu\text{g/kg/hr}$ of recombinant human activated protein C.

23. (cancelled)

24. (cancelled).

25. (currently amended) The method of Claim 21 ~~[[24]]~~, wherein the recombinant human activated protein C is administered by continuous infusion for about 1 ~~[[48]]~~ to about 240 hours.

26. (currently amended) A method of treating thrombotic thrombocytopenic purpura (TTP) in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of recombinant human activated protein C such that a ~~recombinant~~ human activated protein C plasma level of about 2 ng/ml to about 200 ng/ml is achieved.

27. (currently amended) The method of Claim 26 wherein the recombinant human activated protein C is administered by continuous infusion for about 1 ~~[[48]]~~ to about 240 hours.

28. (previously presented) The method of Claim 26 wherein the recombinant human activated protein C is administered first as a bolus then as a continuous infusion.

29. (currently amended) A method of treating a patient suffering from hemolytic uremic syndrome (HUS) which comprises, administering to said patient a dosage of about 1 µg/kg/hr to about 50 µg/kg/hr of recombinant human activated protein C.

30. (currently amended) The method of Claim 29 wherein the dosage is about 5 [[6]] µg/kg/hr to about 30 [[36]] µg/kg/hr of recombinant human activated protein C.

31. (cancelled)

32. (cancelled)

33. (currently amended) The method of Claim 32, wherein the recombinant human activated protein C is administered by continuous infusion for about 1 [[48]] to about 240 hours.

34. (currently amended) A method of treating hemolytic uremic syndrome (HUS) in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of recombinant human activated protein C such that a ~~recombinant~~ human activated protein C plasma level of about 2 ng/ml to about 200 ng/ml is achieved.

35. (currently amended) The method of Claim 34 wherein the recombinant human activated protein C is administered by continuous infusion for about 1 [[48]] to about 240 hours.

36. (previously presented) The method of Claim 34 wherein the recombinant human activated protein C is administered first as a bolus then as a continuous infusion.

37. (new) The method of Claim 22 wherein the dosage is 24 $\mu\text{g/kg/hr}$ of recombinant human activated protein C.

38. (new) The method of Claim 30 wherein the dosage is 24 $\mu\text{g/kg/hr}$ of recombinant human activated protein C.